By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors CAO, Jingtai; HU, Ying; ROMANO, Carmelo; WIEGAND, Stanley J., filed on December 1, 2015, was made available online on June 9, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent appli
Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental New Drug Application to update the label for AVYCAZ with clinical data from a Phase 3 trial evaluating the safety and efficacy of AVYCAZ, in combination with metronidazole, for the treatment of co
SUMMARY: The Food and Drug Administration is announcing the availability of its FDA Adverse Event Reporting System Regional Implementation Specifications for the International Conference on Harmonisation E2B Specification. FDA is making this technical specifications document available to assist interested parties in electronically submitting...
To support the efforts of nurse practitioners who are on the front lines of treating the hundreds of millions of people living in pain 1 in the United States, Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today summarizes efficacy and safety data supporting the use of low-do
Market Research Reports, Inc. has announced the addition of Vietnam Phamaceutical Report Q2/2016 research report to their website www.MarketResearchReports.comLewes, DE 06/23/2016 With 178 drug manufacturers Vietnam pharmaceutical products mostly focus on simple dosage forms and generic form with lower values and overlapping, and comple
Dimension Therapeutics, Inc., a biopharmaceutical company advancing novel, adeno-associated virus gene therapies targeting the liver, a key organ for human metabolism, today announced unanimous approval by the National Institutes of Health's Recombinant DNA Advisory Committee of a Phase 1/ 2 study protocol for DTX301 for the treatment of Ornithin
OPKO Health, Inc. announced that the U.S. Food and Drug Administration has approved RAYALDEE extended release capsules for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25- hydroxyvitamin D levels less than 30 ng/mL. Phillip Frost, CEO and Chairman of OPKO. "RAYALDEE is the fir
Perrigo Company plc, today announced it has received final U.S. Food and Drug Administration clearance for three milk-based, store brand non-GMO infant formulas. Perrigo introduced non-GMO formulas for consumers who prefer non-GMO versions of existing products. Perrigo's CEO, John T. Hendrickson stated, "We know that today's millennial mom is mor
Sandoz Canada announces the launch of S.O.S. "Sandoz Canada is the first pharmaceutical company in the country to have completed the filing process for non-prescription naloxone. Naloxone? Hydrochloride Injection, "said Michel Robidoux, President and General Manager of Sandoz Canada.
BRITISH COLUMBIA, VANCOUVER 06/21/16 VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, pleased to announce that it has received the approvals for Van-Fer tablets and capsules. The iron supplements market in Canada is estimated to be around $75 million per annum, based on IMS
By a News Reporter-Staff News Editor at Managed Care Weekly Digest WASHINGTON- Hearing loss is a significant public health concern, and efforts should be made to provide adults with easier access to and more affordable options for hearing health care, especially for those in underserved and vulnerable populations, says a new report from the Natio
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, pleased to announce that it has entered into a definitive agreement for filing two abbreviated new drug submissions with exclusive marketing rights to Canada from an unnamed, manufacturer. "We are very excited to have signed this.